Rosetta Genomics and Meir Medical Center in Kfar Saba, Israel, will observe nonsmall cell lung cancer patients who were considered for treatment that would have used their immune systems to fight cancer.
Dr. Maya Gottfried, Meir Medical Center's head of oncology and head of lung oncology, will lead the trial, according to a pres release. The companies will complete the study to establish that PD-L1 positive and negative samples vary from each other. Rosetta Genomics and Meir Medical Center aim to establish a microRNA classifier through the study.
Keytruda, Opdivo and Tecentriq are among medications that the Food & Drug Administration has allowed to be used for nonsmall cell lung cancer patients who have either had no success or had success with treatments based on platinum or very precise treatments, the release said.
However, medical professionals want to find a substance that can be quantified and shows that there is a disease or other event happening within the body.